PPAR
Peroxisome proliferator-activated receptors
PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.
PPAR Isoform Specific Products
All Product Categories
-
PPAR Inhibitors
(105)
View all products
-
PPAR Agonists
(336)
View all products
-
PPAR Antagonists
(30)
View all products
-
PPAR Activators
(168)
View all products
-
PPAR Modulators
(41)
View all products
-
PPAR Inducers
(6)
View all products
-
PPAR Controls
(3)
View all products
-
PPAR Ligands
(4)
View all products
-
Peroxisome Proliferator-activated Receptor Proteins
(11)
View all products
-
PPAR alpha Proteins
(2)
View all products
-
PPAR gamma Proteins
(7)
View all products
-
PPAR-delta Proteins
(2)
View all products
-
PPAR Related Products (737)
Related Products (737)
-
Recombinant Proteins (11)
-
Antibodies (4)
-
PPAR Isoform Comparison
-
DB-959
0 ImagesCat. No.: HY-124244CAS No.: 1257641-15-8Synonyms: PPARδ/γ agonist 1DB-959 (PPARδ/γ agonist 1) is a potent PPAR agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD)..
-
Clofibric acid-d4
0 ImagesCat. No.: HY-B1415SCAS No.: 1184991-14-7Synonyms: Chlorofibrinic acid-d4Clofibric acid-d4 is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research.
-
Deutaleglitazar
0 ImagesCat. No.: HY-14728SCAS No.: 2902649-99-2Synonyms: Aleglitazar-d2; R1439-d2; RO0728804-d2
-
GW 590735 sodium
0 ImagesCat. No.: HY-106278ACAS No.: 343322-50-9GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735.
-
GED 0507-34-Levo
0 ImagesCat. No.: HY-W109107CAS No.: 921195-93-9
-
PPARγ agonist 10
0 ImagesCat. No.: HY-163294CAS No.: 2445990-92-9PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells.
-
CAY10506
0 ImagesCat. No.: HY-118988CAS No.: 292615-75-9CAY10506 is a PPARγ ligand that can induce cell death and ROS production in a PPARγ-dependent manner in vitro. CAY10506 exhibits radiosensitizing effects, enhancing γ-radiations-induced apoptosis and caspase-3-mediated poly (ADP-ribose) polymerase (PARP) cleavage. CAY10506 can be used in cancer research.
-
Inolitazone hydrochloride hydrate
0 ImagesCat. No.: HY-14792CCAS No.: 1048002-36-3Synonyms: Efatutazone hydrochloride hydrate; CS-7017 hydrochloride hydrate; RS5444 hydrochloride hydrateInolitazone hydrochloride hydrate (Efatutazone hydrochloride hydrate) is a novel PPARγ high-affinity agonist, with an EC50 value one-fiftieth that of Rosiglitazone (HY-17386), and shows no inhibitory effect on RIE cells that do not express PPARγ. Inolitazone hydrochloride hydrate can be used in the research of cancer.
-
Clofibric acid (Standard)
0 ImagesClofibric acid (Standard) is the analytical standard of Clofibric acid (HY-B1415). This product is intended for research and analytical applications. Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research.
-
PPARγ agonist 15
0 ImagesCat. No.: HY-169404PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC50 of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model.
-
Monascin (Standard)
0 ImagesCat. No.: HY-N6641RCAS No.: 21516-68-7Monascin (Standard) is the analytical standard of Monascin. This product is intended for research and analytical applications. Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist.
-
PPARγ agonist 4
0 ImagesCat. No.: HY-146439CAS No.: 2380227-06-3PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib.
-
Gypenoside XLIX (Standard)
0 ImagesCat. No.: HY-N1990RCAS No.: 94987-08-3Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells.
-
PPARδ agonist 12
0 ImagesCat. No.: HY-174278CAS No.: 2982696-34-2PPARδ agonist 12 (compound 25) is a PPARδ agonist that inhibits the production of inflammatory factors and nitric oxide. PPARδ agonist 12 can also effectively prevent macrophages from infiltrating inflammatory sites and can be used in inflammation research.
-
Bezafibrate-d4
0 ImagesCat. No.: HY-B0637S1CAS No.: 1189452-53-6Synonyms: BM15075-d4
-
SB-219994
0 ImagesCat. No.: HY-105325CAS No.: 177785-17-0SB-219994 is a peroxisome proliferator-activated receptors (PPARs) agonists. SB-219994 can inhibit airway neutrophilia and associated chemoattractants/survival factors. SB-219994 exhibits anti-inflammation effec.
-
Fenofibrate-d4
0 ImagesCat. No.: HY-17356S1CAS No.: 1092484-57-5Fenofibrate-d4 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
-
Ppard Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10924Ppard Rat Pre-designed siRNA Set A contains three designed siRNAs for Ppard gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
OLHHA
0 ImagesCat. No.: HY-139230CAS No.: 1258011-97-0OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD).
